A system may include a mobile application residing on an external device and an inhalation device. The inhalation device may include a mouthpiece, a mouthpiece cover, medicament, and an electronics module comprising a processor. The inhalation device may be configured to both prepare a dose of medicament for delivery to a user and cause the processor to transition between power states when the mouthpiece cover is moved from a closed position to an open position to expose the mouthpiece. The electronics module or the mobile application may be configured to generate usage events based on usage of the inhalation device by the user. The electronics module may also include a pressure sensor, and the electronics module or the mobile application may be configured to determine whether a usage event is a good inhalation event, a fair inhalation event, or a no inhalation event based on feedback from the pressure sensor.

Systems for dense phase transport of frozen and other particles to the respiratory system include a particle source, a delivery chamber for metering boluses of the particles from the source, and a transfer tube for fluidized transport of the particles to a patient interface. A controller may be provided to adjust the rate and amount of the bolus deliver to a patient to control core body temperature and for other purposes.

An inhaler article includes a body extending along a longitudinal axis from a mouthpiece end to a distal end and a capsule cavity defined within the body. The capsule cavity has a length extending along the longitudinal axis. A mouthpiece air channel extends from the capsule cavity to the mouthpiece end. An end cap is disposed within the distal end and extends to the capsule cavity. The end cap includes an air channel extending from the end cap distal end to the end cap inner end. A capsule is disposed within the capsule cavity and has a capsule length. The capsule length is in a range from about 25% to about 99% of the cavity length, or about 50% to about 95% of the cavity length, or about 70% to about 90% of the cavity length, or from about 75% to about 85% of the cavity length, or about 80% of the cavity length.

A system may include a mobile application residing on an external device and an inhalation device. The inhalation device may include a mouthpiece, a mouthpiece cover, medicament, and an electronics module comprising a processor. The inhalation device may be configured to both prepare a dose of medicament for delivery to a user and cause the processor to transition between power states when the mouthpiece cover is moved from a closed position to an open position to expose the mouthpiece. The electronics module or the mobile application may be configured to generate usage events based on usage of the inhalation device by the user. The electronics module may also include a pressure sensor, and the electronics module or the mobile application may be configured to determine whether a usage event is a good inhalation event, a fair inhalation event, or a no inhalation event based on feedback from the pressure sensor.

Dry powder inhalers and dry powder inhaler storage cassettes including a compartment housing an elongate carrier preloaded with a plurality of doses of finely divided powder comprising a biologically active substance, the compartment being configured such that said preloaded doses are sealed within said compartment and such that the carrier may be advanced from the compartment to the chamber through an exit provided with a moisture barrier sealing system, wherein the moisture barrier sealing system is configured and arranged such that it is relaxable during advancement of the carrier, said sealing system being in sealing configuration prior to an advancement of the carrier, relaxed upon an advancement of the carrier and returned to its sealing configuration at the latest after release of the powder associated with said area of the carrier.

Inhaler testing apparatus includes a frame, a rotatable carousel rotatably mounted on said frame and that support tubes each having a closed end and an open end, an inhaler retaining apparatus on said frame that retains an inhaler being tested, and actuating mechanisms on the frame for moving the inhaler retaining apparatus in two directions, for shaking and actuating the inhaler being tested. A control unit controls rotation of the carousel and the actuating mechanisms to move the carousal relative to the inhaler being tested to cause controlled shaking of the inhaler and delivery of material from the inhaler into each tube. Analysis of the material in the tubes constitutes a test of the inhaler.

The disclosure describes powder inhalers and dry powder inhaler storage cassettes that include a compartment housing an elongate carrier preloaded with a plurality of doses of finely divided powder comprising a biologically active substance. The compartment is configured such that the preloaded doses are sealed within the compartment and such that the carrier may be advanced from the compartment to the chamber through an exit provided with a moisture barrier sealing system. The moisture barrier sealing system is configured and arranged such that it is relaxable during advancement of the carrier. The sealing system is in sealing configuration prior to an advancement of the carrier, is relaxed upon an advancement of the carrier and is returned to its sealing configuration at the latest after release of the powder associated with the area of the carrier.

Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (C.sub.max) of at least 30 ng/mL, with (b) a mean time to C.sub.max (T.sub.max) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.

An aerosol generator for generating an inhalation aerosol from an inhalation liquid, includes an intake duct for guiding air to a mouth of a user, and a nozzle, arranged in the intake duct for injecting the inhalation liquid into the intake duct. The nozzle is arranged for generating a Rayleigh droplet train of the inhalation liquid propagating along a droplet train propagation path. The intake duct includes at least two first orifices having at least partly opposing discharging directions extending towards the droplet train propagation path. The at least two first orifices are configured for providing respective first air streams in at least partly opposing directions so as to interact in the droplet train propagation path.

An apparatus for delivering a powdered agent into a subject's body may include a first passage for receiving a pressurized gas. The apparatus also may include a container housing a powdered agent. The container may be in fluid connection with the first passage. At least a portion of the pressurized gas is introduced into the powdered agent in the container to fluidize the powdered agent. The apparatus also may include a second passage for receiving the powdered agent from the container. In a first configuration of the apparatus, the second passage may not be in fluid connection with the container. In a second configuration of the apparatus, the second passage may be in fluid connection with the container. The apparatus may be configured to transition between the first configuration and the second configuration.